21 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 6 Phase 3, 5 Phase 4, 3 Phase 1, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 4 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Basal insulin: new trials by email Literature Review of Basal insulin trials Research Report on Basal insulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes Technosphere Insulin, Basal insulin - Type 1 Diabetes Mellitus | Phase 2 | Recruiting | Mannkind Corporation | 100 | 2026-02-04 | 2026-08-13 |
| A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) LY3938577, Placebo, Insulin Degludec - Healthy, Type 1 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 121 | 2024-05-15 | 2026-10-06 |
| Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1) - Diabetes Mellitus, Type 2 | Completed | Novo Nordisk A/S | 156 | 2024-04-30 | 2025-03-21 | |
| INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Afrezza, insulin degludec, Rapid-acting Insulin Analog - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Mannkind Corporation | 141 | 2023-07-07 | 2024-08-09 |
| Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor Basal insulin, Dexcom Continuous Glucose Monitoring (CGM) - Type 2 Diabetes | Phase 1 | Active not recruiting | DexCom, Inc. | 45 | 2023-04-11 | 2026-07-02 |
| Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease GLP-1 receptor agonist, basal insulin - Type 2 Diabetes, Chronic Kidney Diseases | Completed | LMC Diabetes & Endocrinology Ltd. | 348 | 2023-02-15 | 2024-02-01 | |
| Afrezza® INHALE-1 Study in Pediatrics Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Mannkind Corporation | 319 | 2021-09-29 | 2025-05-06 |
| A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes Basal Insulin - Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | Phase 4 | Withdrawn | Eli Lilly and Company | 2021-08-16 | 2021-08-24 | |
| BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes DPP4, GLP-1 receptor agonist, Basal Insulin - Diabetes Mellitus, Type 2 | Unknown | Brigham and Women's Hospital | 550000 | 2021-07-01 | 2023-06-22 | |
| Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin GLP-1 receptor agonist, Insulin - Diabetes Mellitus, Type 2 | Unknown | Brigham and Women's Hospital | 20000 | 2019-05-01 | 2020-07-09 | |
| Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia Insulin - Hyperglycemia | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2019-04-04 | 2023-01-20 |
| A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) Lixisenatide (AVE0010), Placebo, Basal Insulin - Type 2 Diabetes Mellitus | Phase 1 | Completed | Sanofi | 23 | 2017-05-17 | 2022-04-25 |
| Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan Lixisenatide (AVE0010), Sulfonylurea, metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Sanofi | 184 | 2017-02-23 | 2022-04-25 |
| Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy Empagliflozin 25 MG, INS - Diabetes Mellitus, Type 2 | Unknown | Chungbuk National University Hospital | 300 | 2017-01-01 | 2022-07-20 | |
| Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? GLP1 receptor agonist, basal insulin, SGLT2 inhibitor - Type 2 Diabetes Mellitus | Not applicable | Completed | University of California, San Francisco | 22 | 2016-08-01 | 2020-11-10 |
| Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment exenatide once weekly, basal insulin - Type 2 Diabetes | Completed | AstraZeneca | 6024 | 2015-08-01 | 2018-03-29 | |
| Clinical Outcomes of Exenatide Versus Basal Insulin exenatide once weekly, exenatide twice daily, basal insulin - Type 2 Diabetes | Completed | AstraZeneca | 18000 | 2015-06-30 | 2017-03-29 | |
| Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins exenatide once weekly, basal insulin - Type 2 Diabetes | Completed | AstraZeneca | 7000 | 2014-10-28 | 2017-03-29 | |
| A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to Ertugliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 621 | 2013-12-13 | 2018-09-10 |
| Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes Faster-acting insulin aspart, basal insulin - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 323 | 2013-09-23 | 2019-06-12 |
Showing 20 of 27. Sign in to see all of them.
Diabetes Mellitus, Type 2 (21) · Diabetes Mellitus (7) · Insulin Resistance (6) · Diabetes Mellitus, Type 1 (5) · Hyperglycemia (4) · Respiratory Aspiration (3) · Renal Insufficiency, Chronic (1)
AstraZeneca (4) · Sanofi (4) · Mannkind Corporation (3) · Brigham and Women's Hospital (2) · Eli Lilly and Company (2) · Novo Nordisk A/S (2) · Chungbuk National University Hospital (1) · DexCom, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · LMC Diabetes & Endocrinology Ltd. (1) · Mayo Clinic (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · US Department of Veterans Affairs (1) · University of California, San Francisco (1)
United States (17) · India (3) · Mexico (3) · Turkey (Türkiye) (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Chile (1) · Denmark (1) · Egypt (1)
Anita M Loughlin, Ph.D (2) · Alexander Abitbol, MD (1) · Alexander Turchin, MD, MS (1) · Craig Currie, Ph.D (1) · David D'Alessio, MD (1) · Eu Jeong Ku, MD, PhD (1) · Irl B. Hirsch, MD (1) · James Malone, MD (1) · Jeffrey L Probstfield, MD (1) · Jessica M Franklin, PHD (1)
PMID 31956422, PMID 15616226, PMID 22564709, PMID 23628617, PMID 24092826, PMID 25130920, PMID 26039935, PMID 26068865, PMID 27208320, PMID 28345792, PMID 28857451, PMID 29802636, PMID 30547388, PMID 30614616, PMID 31064361, PMID 31797522, PMID 32236732, PMID 32302665, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 34213819, PMID 35411611, PMID 36763328, PMID 36809495, PMID 37369826, PMID 37435938, PMID 39113258, PMID 42573729
2023 (1)